Polycystic Kidney Disease (PKD) Therapeutics Pipeline, 2017 - Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

  • ID: 4451359
  • Report
  • Region: Global
  • 86 pages
  • P&S Market Research
1 of 4

FEATURED COMPANIES

  • Exelixis, Inc.
  • XORTX Pharma Corp
  • MORE
Polycystic kidney disease currently exhibits a growing pipeline with approximately 16 drug candidates.

Polycystic Kidney Disease Pipeline in 2017

The study analyzed that the polycystic kidney disease (PKD) therapeutics pipeline comprises approximately 16 drug candidates in different stages of development. PKD affects kidney along with other organs, in which development of cyst interrupts the ability to filter the waste products from blood. The disease is mostly related to high blood pressure, blood in urine, pain in back, kidney stones and heart valve abnormalities. Enlargement of cyst may lead to kidney failure which can in turn impact other organs. People with PKD are at a risk of developing aneurysm in aorta or in blood vessels in base of the brain. The disease can be categorized into two types, as autosomal dominant polycystic kidney disease (AKPKD), and autosomal recessive polycystic kidney disease (ARPKD). AKPKD generally diagnosed in adulthood, while ARPKD diagnosed in earliest months of life.

Insights on pipeline segments

According to the research findings, most of the drug candidates of the PKD are being developed to be administered by the oral route.

Surge in the development of Pre-Clinical and Discovery Drug Candidates

Many pharmaceutical companies are involved in the development of therapeutic compounds by overcoming the challenges, that are effective in the treatment of PKD. They are focusing on developing the maximum drug candidates in the Pre-Clinical and Discovery stage of development. The pipeline consists of approximately eight drug candidates in the Pre-Clinical stage. GLG Pharma is in the process of developing two drug candidates in Pre-Clinical stage.

Increased Funding by the Government Organizations Contributing Immensely in Pipeline Growth

Novatarg Pharmaceuticals, received $3.2 million funding by Small Business Innovation Research (SBIR), a part of governmental agencies of National Institutes of Health, to further conduct clinical study in PKD. Novatarg Pharmaceuticals, is in the process of research and development activities of NT 1044. Through the funding, NovaTarg Pharmaceuticals had further planned to progress drug candidates for PKD and type II diabetes mellitus. In addition, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is also supporting the pharmaceutical companies to conduct clinical study and research on PKD to improve patient health.

Some of the key players developing drugs for the treatment of PKD therapeutics include Otsuka Pharmaceutical Co., Ltd., Exelixis, Inc., and XORTX Pharma Corp.

Polycystic Kidney Disease Therapeutics Pipeline Analysis
  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Exelixis, Inc.
  • XORTX Pharma Corp
  • MORE
Chapter 1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.4 Key Stakeholders

Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook
4.1 Overview
4.2 Key Drivers
4.3 Key Barriers
4.4 Polycystic Kidney Diseases Therapeutics Pipeline Analysis
4.4.1 Pipeline Analysis by Phase
4.4.2 Pipeline Analysis by Molecule Type
4.4.3 Pipeline Analysis by Route of Administration
4.4.4 Pipeline Analysis by Company

Chapter 5. Polycystic Kidney Diseases Therapeutics Pipeline Analysis by Phase (2017)
5.1 Filed: Drug profiles
5.1.1 Pre-Clinical Study
5.1.2 Pre-Clinical Results
5.1.3 Clinical Trials
5.1.4 Clinical Results
5.1.5 Strategic Development
5.1.6 Designation
5.1.7 Grants
5.1.8 Patent
5.1.9 Technology
5.2 Phase II: Drug profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.3 Phase I: Drug profiles
5.3.1 Pre-Clinical Study
5.3.2 Pre-Clinical Results
5.3.3 Clinical Trials
5.3.4 Clinical Results
5.3.5 Strategic Development
5.3.6 Designation
5.3.7 Grants
5.3.8 Patent
5.3.9 Technology
5.4 Pre-Clinical: Drug profiles
5.4.1 Pre-Clinical Study
5.4.2 Pre-Clinical Results
5.4.3 Strategic Development
5.4.4 Designation
5.4.5 Grants
5.4.6 Patent
5.4.7 Technology
5.5 Discovery: Drug profiles
5.5.1 Strategic Development
5.5.2 Designation
5.5.3 Grants
5.5.4 Patent
5.5.5 Technology
5.6 Inactive: Drug profiles
5.6.1 Pre-Clinical Study
5.6.2 Pre-Clinical Results
5.6.3 Clinical Trials
5.6.4 Clinical Results
5.6.5 Strategic Development
5.6.6 Designation
5.6.7 Grants
5.6.8 Patent
5.6.9 Technology

Chapter 6. Clinical Trials Analysis
6.1 Clinical Trials by Region
6.2 Clinical Trials by Trial Status

Chapter 7. Competitive Landscape
7.1 Key Players Benchmarking for Polycystic Kidney Disease Therapeutics Pipeline
7.2 SWOT Analysis of Polycystic Kidney Disease Therapeutics Pipeline
7.2.1 Strengths
7.2.2 Weaknesses
7.2.3 Opportunities
7.2.4 Threats

Chapter 8. Company Profiles
8.1 Business Overview
8.2 Product and Service Offerings

Chapter 9. Appendix
9.1 Abbreviations
9.2 Related Reports

List of Tables
Pipeline Analysis Of Polycystic Kidney Disease Therapeutics, By Company (2017)
Description Of Filed Stgae Drug Candidates
Clinical Trials Of Filed Stgae Drug Candidates
Description Of Phase II Drug Candidates
Clinical Trials Of Phase II Drug Candidates
Description Of Phase I Drug Candidates
Clinical Trials Of Phase I Drug Candidates
Description Of Pre-Clinical Drug Candidates
Description Of Discovery Drug Candidates
Description Of Inactive Drug Candidates
Companies - at a Glance

List of Figures
Research Methodology
Split Of Primary And Secondary Research
Breakdown Of Primary Researchby Industry Participant
Breakdown Of Primary Researchby Company Type
Polycystic Kidney Diseases Therapeutics Drug Candidates Under Development (2017)
Polycystic Kidney Diseease Therapeutics Pipeline Split, By Molecule Type (2017)
Polycystic Kidney Disease Therapeutics Pipeline Split, By Route Of Administration (2017)
Breakdown Of Clinical Trials, By Region
Breakdown Of Clinical Trials, By Trial Status
Key Players Benchmarking
Swot Analysis
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Exelixis, Inc.
  • tsuka Pharmaceutical Co., Ltd.
  • XORTX Pharma Corp
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll